摘要
美国一项针对黑色素瘤,滑膜肉瘤和多发性骨髓瘤患者的在美国进行的第一阶段CRISPR基因编辑试验的前瞻性研究提供了希望,即基因编辑工具可以有效治疗人类疾病。然而,首先在人类第一阶段临床试验中,首要的伦理挑战是知道什么时候在从临床前研究获得的安全性和有效性数据的基础上启动此类试验在伦理上是可接受的。如果通知试验设计的临床前研究本身设计得不好,导致临床前证据的质量不足,那么对临床研究的科学有效性的伦理要求可能就不能满足。反过来,这可能意味着1期临床试验将是不安全的,试验参与者将面临无潜在风险的风险。为了帮助申办者,研究人员,临床研究者和审稿人决定什么时候在伦理上接受启动人类第一阶段CRISPR基因编辑临床试验,已经开发了结构化的过程来评估和最小化临床前和临床研究之间的翻译距离。这些过程引起人们对内部有效性,结构有效性和外部效度的各种特征的关注。支持性证据的可信度也需要特别注意乐观偏见,财务利益冲突和发表偏倚。我们批判性地研究了使用这些工具来验证美国第一阶段CRISPR基因编辑癌症试验的临床前证据。我们的结论是,所提出的试验不能满足科学有效性的伦理要求,因为用于通知试验设计的辅助临床前证据是有缺陷的。
关键词: CRISPR,第一阶段,癌症,基因编辑,研究伦理,科学有效性。
Current Gene Therapy
Title:First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Volume: 17 Issue: 4
关键词: CRISPR,第一阶段,癌症,基因编辑,研究伦理,科学有效性。
摘要: A prospective first-in-human Phase 1 CRISPR gene editing trial in the United States for patients with melanoma, synovial sarcoma, and multiple myeloma offers hope that gene editing tools may usefully treat human disease. An overarching ethical challenge with first-in-human Phase 1 clinical trials, however, is knowing when it is ethically acceptable to initiate such trials on the basis of safety and efficacy data obtained from pre-clinical studies. If the pre-clinical studies that inform trial design are themselves poorly designed – as a result of which the quality of pre-clinical evidence is deficient – then the ethical requirement of scientific validity for clinical research may not be satisfied. In turn, this could mean that the Phase 1 clinical trial will be unsafe and that trial participants will be exposed to risk for no potential benefit. To assist sponsors, researchers, clinical investigators and reviewers in deciding when it is ethically acceptable to initiate first-in-human Phase 1 CRISPR gene editing clinical trials, structured processes have been developed to assess and minimize translational distance between pre-clinical and clinical research. These processes draw attention to various features of internal validity, construct validity, and external validity. As well, the credibility of supporting evidence is to be critically assessed with particular attention to optimism bias, financial conflicts of interest and publication bias. We critically examine the pre-clinical evidence used to justify the first-inhuman Phase 1 CRISPR gene editing cancer trial in the United States using these tools.
We conclude that the proposed trial cannot satisfy the ethical requirement of scientific validity because the supporting pre-clinical evidence used to inform trial design is deficient.
Export Options
About this article
Cite this article as:
First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?, Current Gene Therapy 2017; 17 (4) . https://dx.doi.org/10.2174/1566523217666171121165935
DOI https://dx.doi.org/10.2174/1566523217666171121165935 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV
Mini-Reviews in Medicinal Chemistry Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Modeling Anti-HIV Compounds: The Role of Analogue-Based Approaches
Current Computer-Aided Drug Design RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Active Targeted Drug Delivery for Microbes Using Nano-Carriers
Current Topics in Medicinal Chemistry Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry